3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
46
Lung Neoplasms
29
Neoplasms
26
Colorectal Neoplasms
21
Prostatic Neoplasms
16
Uterine Cervical Neoplasms
9
Fatigue
9
Hematologic Neoplasms
8
Lymphoma
7
Hematopoietic and Lymphatic System Neoplasm
7
Anxiety Disorders
7
Papillomavirus Infections
6
Melanoma
6
Neoplasm Metastasis
5
Multiple Myeloma
5
Gastrointestinal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Skin Neoplasms
4
Ovarian Neoplasms
4
Obesity-Related Malignant Neoplasm
4
Obesity
4
Motor Activity
4
Hematopoietic and Lymphoid System Neoplasm
4
Head and Neck Neoplasms
4
Depression
4
Breast Carcinoma In Situ
4
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Interventions
padeliporfin
5
Nivolumab
3
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Radiosurgery
2
Cyclophosphamide
2
Cisplatin
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
spartalizumab
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
lutetium Lu 177 dotatate
1
guadecitabine
1
genexol-PM
1
durvalumab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Site
×
Educational Status
×
Clear all
NCT04679675
2023-09-18
STEP
Kaiser Permanente
Phase NA
Completed
32,771 enrolled
11 charts